Imaging of Prostate-Specific Membrane Antigen Using [18F]DCFPyL

Steven P Rowe; Michael A Gorin; Martin G Pomper

doi:10.1016/j.cpet.2017.02.006

Imaging of Prostate-Specific Membrane Antigen Using [¹⁸F]DCFPyL

PET Clin. 2017 Jul;12(3):289-296. doi: 10.1016/j.cpet.2017.02.006. Epub 2017 Apr 1.

Authors

Steven P Rowe¹, Michael A Gorin², Martin G Pomper³

Affiliations

¹ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA. Electronic address: srowe8@jhmi.edu.
² Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA.
³ The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287, USA.

PMID: 28576167
DOI: 10.1016/j.cpet.2017.02.006

Abstract

Prostate-specific membrane antigen (PSMA) has been explored as a target for molecular imaging of prostate cancer and other malignancies that express PSMA in their tumor-associated neovasculature. Although several PSMA-targeted radiotracers labeled with a variety of radionuclides have been reported, positron-emitting radiotracers labeled with ¹⁸F are of particular interest. One such compound, the small molecule PSMA inhibitor [¹⁸F]DCFPyL, has demonstrated initial success. This article reviews the literature on this radiotracer, including radiosynthetic approaches to the molecule, data that are available from preclinical experiments, and evidence to date of the clinical utility of this agent in prostate cancer and clear cell renal cell carcinoma.

Keywords: DCFPyL; Prostate cancer; Radiopharmaceutical.

Publication types

Review

MeSH terms

Antigens, Surface / analysis*
Glutamate Carboxypeptidase II / analysis*
Humans
Male
Positron-Emission Tomography
Prostatic Neoplasms / chemistry*
Prostatic Neoplasms / diagnostic imaging*
Radiopharmaceuticals
Tomography, X-Ray Computed

Substances

Antigens, Surface
Radiopharmaceuticals
FOLH1 protein, human
Glutamate Carboxypeptidase II